Rubby Das, Nilam Subedi, S. Rajbhandari, Gahana Gurung
{"title":"口服米非司酮在延长妊娠期引产中的疗效和安全性","authors":"Rubby Das, Nilam Subedi, S. Rajbhandari, Gahana Gurung","doi":"10.3126/jkmc.v11i1.45493","DOIUrl":null,"url":null,"abstract":"Background: Induction of labour implies, achieving vaginal delivery by stimulating uterine contractions before spontaneous onset of labour. Prolonged pregnancy exceeding duration of expected date of delivery is associated with increased risk to foetus and most common indication for induction of labour. Objectives: To study the safety and efficacy of oral mifepristone in induction of labour in prolonged pregnancy. Methods: This experimental study was carried out in Universal College of Medical Sciences Teaching Hospital, Bhairahawa between June 2016 to June 2017 after ethical clearance. Total 102 women were included in the study with 51 participants in the study group (mifepristone) and 51 in the control group (misoprostol). Data were expressed in frequency and mean ± SD and analysed using Independent “t” test and Chi-square test. A p-value of <0.05 was considered significant. Safety and efficacy of the drug was analysed with regards to maternal and perinatal outcome. Results: Single dose of mifepristone was sufficient enough for successful induction in 40 (78.43%) women in study group. Time interval from induction to delivery had maximum frequency of 6-12 hours in both groups (p-value 0.13). The active phase of labour lasted for 2-6 hours in 38 (74.5%) women of the study group. Around 27 (42.9%) women of study group required augmentation of labour and 49 (96.1%) women had vaginal delivery. There was no significant difference in perinatal outcome between both the groups. Conclusion: Mifepristone combined with or without augmentation is safe, efficient, economical, and convenient induction agent for initiation of labour in prolonged pregnancies.","PeriodicalId":254049,"journal":{"name":"Journal of Kathmandu Medical College","volume":"10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of oral mifepristone in induction of labour in prolonged pregnancy\",\"authors\":\"Rubby Das, Nilam Subedi, S. Rajbhandari, Gahana Gurung\",\"doi\":\"10.3126/jkmc.v11i1.45493\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Induction of labour implies, achieving vaginal delivery by stimulating uterine contractions before spontaneous onset of labour. Prolonged pregnancy exceeding duration of expected date of delivery is associated with increased risk to foetus and most common indication for induction of labour. Objectives: To study the safety and efficacy of oral mifepristone in induction of labour in prolonged pregnancy. Methods: This experimental study was carried out in Universal College of Medical Sciences Teaching Hospital, Bhairahawa between June 2016 to June 2017 after ethical clearance. Total 102 women were included in the study with 51 participants in the study group (mifepristone) and 51 in the control group (misoprostol). Data were expressed in frequency and mean ± SD and analysed using Independent “t” test and Chi-square test. A p-value of <0.05 was considered significant. Safety and efficacy of the drug was analysed with regards to maternal and perinatal outcome. Results: Single dose of mifepristone was sufficient enough for successful induction in 40 (78.43%) women in study group. Time interval from induction to delivery had maximum frequency of 6-12 hours in both groups (p-value 0.13). The active phase of labour lasted for 2-6 hours in 38 (74.5%) women of the study group. Around 27 (42.9%) women of study group required augmentation of labour and 49 (96.1%) women had vaginal delivery. There was no significant difference in perinatal outcome between both the groups. Conclusion: Mifepristone combined with or without augmentation is safe, efficient, economical, and convenient induction agent for initiation of labour in prolonged pregnancies.\",\"PeriodicalId\":254049,\"journal\":{\"name\":\"Journal of Kathmandu Medical College\",\"volume\":\"10 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Kathmandu Medical College\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3126/jkmc.v11i1.45493\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Kathmandu Medical College","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3126/jkmc.v11i1.45493","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:引产是指在自然分娩前通过刺激子宫收缩实现阴道分娩。妊娠期延长超过预产期与胎儿风险增加有关,是引产最常见的指征。目的:探讨口服米非司酮用于延长妊娠引产的安全性和有效性。方法:本实验研究于2016年6月至2017年6月在Bhairahawa市通用医学学院教学医院进行,经伦理审查。研究共纳入102名妇女,其中51名受试者为研究组(米非司酮),51名受试者为对照组(米索前列醇)。数据以频率和均数±SD表示,采用独立t检验和卡方检验进行分析。p值<0.05为显著性。对该药的安全性和有效性进行了孕产妇和围产期结局分析。结果:研究组40例(78.43%)妇女单剂量米非司酮足以诱导成功。两组从诱导到分娩的时间间隔最大频率为6 ~ 12 h (p值0.13)。研究组中38例(74.5%)产妇产程活跃期持续2-6小时。研究组中约有27名(42.9%)妇女需要增加产程,49名(96.1%)妇女阴道分娩。两组围产儿结局无显著差异。结论:米非司酮联合或不联合助产是一种安全、有效、经济、方便的延长妊娠引产药物。
Efficacy and safety of oral mifepristone in induction of labour in prolonged pregnancy
Background: Induction of labour implies, achieving vaginal delivery by stimulating uterine contractions before spontaneous onset of labour. Prolonged pregnancy exceeding duration of expected date of delivery is associated with increased risk to foetus and most common indication for induction of labour. Objectives: To study the safety and efficacy of oral mifepristone in induction of labour in prolonged pregnancy. Methods: This experimental study was carried out in Universal College of Medical Sciences Teaching Hospital, Bhairahawa between June 2016 to June 2017 after ethical clearance. Total 102 women were included in the study with 51 participants in the study group (mifepristone) and 51 in the control group (misoprostol). Data were expressed in frequency and mean ± SD and analysed using Independent “t” test and Chi-square test. A p-value of <0.05 was considered significant. Safety and efficacy of the drug was analysed with regards to maternal and perinatal outcome. Results: Single dose of mifepristone was sufficient enough for successful induction in 40 (78.43%) women in study group. Time interval from induction to delivery had maximum frequency of 6-12 hours in both groups (p-value 0.13). The active phase of labour lasted for 2-6 hours in 38 (74.5%) women of the study group. Around 27 (42.9%) women of study group required augmentation of labour and 49 (96.1%) women had vaginal delivery. There was no significant difference in perinatal outcome between both the groups. Conclusion: Mifepristone combined with or without augmentation is safe, efficient, economical, and convenient induction agent for initiation of labour in prolonged pregnancies.